Passa al contenuto
Merck
Tutte le immagini(2)

Key Documents

C9756

Sigma-Aldrich

Colecalciferolo

≥98% (HPLC)

Sinonimo/i:

(+)-Vitamina D3, 7-deidrocolesterolo attivato, Calciol

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C27H44O
Numero CAS:
Peso molecolare:
384.64
Beilstein:
2339331
Numero CE:
Numero MDL:
Codice UNSPSC:
12352209
eCl@ss:
34058003
ID PubChem:
NACRES:
NA.26

Origine biologica

synthetic (organic)

Livello qualitativo

Saggio

≥98% (HPLC)

Forma fisica

powder

tecniche

HPLC: suitable

Colore

white to off-white

Punto di fusione

83-86 °C (lit.)

Temperatura di conservazione

2-8°C

Stringa SMILE

CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C

InChI

1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
QYSXJUFSXHHAJI-YRZJJWOYSA-N

Informazioni sul gene

human ... VDR(7421)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Cholecalciferol acts as a hormone precursor since it requires two stages of metabolism: first to 25-hydroxycholecalciferol; then to 1α, 25-dihydroxycholecalciferol. One unit (U.S.P. or international) is defined as the activity of 0.025 μg of vitamin D3 contained in the USP vitamin D reference standard.
Cholecalciferol is sourced either through the diet or exposing skin to ultraviolet rays. Oral administration of vitamin D3 is readily absorbed and is stored in adipose tissue.

Applicazioni


  • Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.: This study delves into the significant roles of cholecalciferol in modulating the renal-bone axis, inflammatory responses, and iron metabolism in elderly patients with renal impairment. Through vitamin D supplementation, researchers observed pivotal changes that could guide future therapeutic strategies (Christodoulou M et al., 2024).

  • Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study.: This clinical trial assesses the efficacy of cholecalciferol in improving the health outcomes of patients with multiple sclerosis. The use of cholecalciferol potentially enhances neurological function and reduces disease progression, illustrating its vital role in neurodegenerative disease management (Maghbooli Z et al., 2024).

  • Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway.: This pivotal research links cholecalciferol to the reduction of COVID-19 severity through its regulatory effects on the NLRP3 inflammasome pathway. The findings underscore the potential of vitamin D as a modulatory agent in the immune response against viral infections (Khalil B et al., 2024).

  • Effects of Vitamin D Supplementation on Central Hemodynamic Parameters and Autonomic Nervous System in Obese or Overweight Individuals.: This randomized controlled trial explores how cholecalciferol supplementation can affect cardiovascular and autonomic functions in obese or overweight patients, providing insights into its benefits beyond bone health and into cardiovascular regulation (Faria ACC et al., 2024).


Azioni biochim/fisiol

La vitamina D agisce attraverso un recettore che è un membro della superfamiglia dei fattori di trascrizione ligando-dipendenti. Modula la proliferazione e la differenziazione sia delle cellule normali che tumorali. Ha effetti antiproliferativi e antimetastatici sulle cellule del cancro della mammella, del colon e della prostata. I recettori della vitamina D attivati nell'intestino e nelle ossa sono responsabili della regolazione dell'assorbimento e dell'omeostasi del calcio.
Deficiency of vitamin D is often observed in chronic kidney disease.

Stoccaggio e stabilità

Cholecalciferol C9756 is packaged under argon gas. If it is stored unopened at 2-8°C and protected from light, this product should be stable for a minimum of three years. Unused portions should be stored under nitrogen or argon gas. Deterioration is negligible after storage of one year in amber-evaculated ampules at refrigerator temperatures. It is oxidized and inactivated by moist air within a few days.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

Skull and crossbonesHealth hazard

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Clinical Veterinary Toxicology, 448-448 (2003)
Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters
Matias P, et al.
Clinical journal of the American Society of Nephrology : CJASN, CJN-06510909 (2010)
Lin Fu et al.
Journal of immunology (Baltimore, Md. : 1950), 203(5), 1198-1207 (2019-07-19)
It is increasingly recognized that excessive glucocorticoids induce fetal intrauterine growth restriction (IUGR). Placental 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2), a glucocorticoid-catalyzing enzyme, prevents active glucocorticoids from maternal circulation into the fetus, thus protecting against IUGR. Previous studies demonstrated gestational LPS exposure
Stefan Pilz et al.
Hypertension (Dallas, Tex. : 1979), 65(6), 1195-1201 (2015-03-25)
Vitamin D deficiency is a risk factor for arterial hypertension, but randomized controlled trials showed mixed effects of vitamin D supplementation on blood pressure (BP). We aimed to evaluate whether vitamin D supplementation affects 24-hour systolic ambulatory BP monitoring values
Anders Burild et al.
Steroids, 98, 72-79 (2015-03-01)
Information regarding the endogenous storages of vitamin D3 after cutaneous vitamin D synthesis compared to oral vitamin D3 supplementation is sparse. Furthermore it is not known whether vitamin D3 can be stored for later use during periods of shortages of

Articoli

Vitamin D and Prevention of Human Disease

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.